The inlay remains implanted at the time of this report and is therefore not available for evaluation.The device history record review of the manufacturing lot was performed and there were no discrepancies or unusual findings related to the reported issue.Corneal haze, decreased vision, and increased visual symptoms are listed in the device labeling as known potential risks.(b)(4).
|
The subject was enrolled in the ide clinical trial and underwent implantation of the investigational corneal inlay in the right eye on (b)(6) 2013.Six months postoperatively, the patient presented with grade 2 central corneal haze in the operative eye, with recurrent haze throughout the course of the study.The haze was associated with visual disturbances (halos, glare, double vision, and ghost images) that significantly interfered with the activities of daily living, including driving at night and depth perception.The corneal haze resulted in a decrease in best corrected distance visual acuity (bcdva) from 20/20 (preoperatively) to 20/25 at onset.At last examination on (b)(6) 2017, corneal haze persisted and bcdva decreased to 20/32.The inlay is scheduled for explantation on (b)(6) 2017.According to the surgeon, the patient's ocular history (dry eye and meibomian gland dysfunction) was a contributing factor.Additional information is being requested.
|